Gene · 4605
Papers2,561
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,561
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients]. | Arkh Patol | 2026 | 41591352 | PubTator, text mining | PubMed |
| Hypoxic glycolysis-driven histone lactylation activates NHE7 to promote endometrial cancer progression via COX6C-mediated endoplasmic reticulum stress. | Apoptosis | 2026 | 41575611 | PubTator, text mining | PubMed |
| Machine learning prediction for AML based on 3D genome selected circRNA. | NPJ Syst Biol Appl | 2026 | 41559113 | PubTator, text mining | PubMed |
| Long non-coding RNAs and therapeutic resistance in multiple myeloma: from molecular insights to clinical applications. | Clin Exp Med | 2026 | 41547689 | PubTator, text mining | PubMed |
| Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors. | Sci Adv | 2026 | 41544174 | PubTator, text mining | PubMed |
| Integrated Network Analysis Reveals a Directly Regulatory Network of FOXM1 Associated With the Cell Cycle in Lung Adenocarcinoma. | Bioinform Biol Insights | 2026 | 41541229 | PubTator, text mining | PubMed |
| FOXM1 regulates platelet-induced anoikis resistance in pancreatic cancer cells. | Cell Commun Signal | 2026 | 41535944 | PubTator, text mining | PubMed |
| Upregulation of MYBL2 ameliorates senescence of nucleus pulposus cells in degenerative intervertebral discs based on RNA-sequencing analysis. | J Mol Histol | 2026 | 41495454 | PubTator, text mining | PubMed |
| FBXW7 Inhibited M2 Macrophage Polarization in Endometrial Cancer by Reducing CCL2 Secretion Through Ubiquitination of MYBL2 Subtitle: The Role of FBXW7 on M2 Macrophage Polarization in EC. | Biochem Genet | 2026 | 41484508 | PubTator, text mining | PubMed |
| Prognostic value of MYBL2 and its potential implications for immunotherapy: a study of bioinformatics and experimental validation. | Br J Cancer | 2026 | 41184628 | PubTator, text mining | PubMed |
| Data-Driven Discovery of a Key Regulator Cyclin A2 as a Promising Therapeutic Target in Hormone-Sensitive Cancers. | Mol Biotechnol | 2026 | 40936038 | PubTator, text mining | PubMed |
In Silico Transcriptomic Analysis for Identification of Potential Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Cervical Cancer using a Hybrid Genetic Algorithm-Support Vector Machine Approach. | Arch Iran Med | 2025 | 41852002 | PubTator, text mining | PubMed |
| Regulation of INSM1 Gene Expression and Neuroendocrine Differentiation in High-Risk Neuroblastoma. | Biology (Basel) | 2025 | 41514864 | PubTator, text mining | PubMed |
| Multi-omics investigation reveals molecular determinants of cancer cell evolution on soft extracellular matrix. | bioRxiv | 2025 | 41446202 | PubTator, text mining | PubMed |
| Clinical Significance of MYBL2 Expression in Hepatocellular Carcinoma: Impact on Overall Survival. | Onco Targets Ther | 2025 | 41424740 | PubTator, text mining | PubMed |
| Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer. | Sci Rep | 2025 | 41402347 | PubTator, text mining | PubMed |
| MYBL2 regulates the expression of CENPF in lung adenocarcinoma and promotes tumor development and metastasis through AKT pathway activation. | Eur J Med Res | 2025 | 41388437 | PubTator, text mining | PubMed |
| Transcription Factor Networks Drive Tumor Progression and Immune Microenvironment Remodeling in Hepatocellular Carcinoma. | Cancers (Basel) | 2025 | 41374989 | PubTator, text mining | PubMed |
| Network Pharmacology and Transcriptomic Analysis Reveal the Mechanism by Which Ginsenoside CK Remodels the Tumor Immune Microenvironment to Inhibit Liver Cancer Progression. | Chem Biol Drug Des | 2025 | 41293954 | PubTator, text mining | PubMed |
| CircFAT1(e2) acts as a sponge for miR-30e-5p and inhibits glioma progression by regulating MYBL2-mediated cell proliferation. | Discov Oncol | 2025 | 41284124 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4605/papers?page=4